DDInter44 DDInter1676
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck. It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Alfuzosin {u} (Compound) resembles {v} (Compound) Terazosin
Alfuzosin {u} (Compound) resembles {v} (Compound) Prazosin
Alfuzosin {u} (Compound) binds {v} (Gene) ADRA1A
Alfuzosin {u} (Compound) upregulates {v} (Gene) PAK1
Alfuzosin {u} (Compound) downregulates {v} (Gene) RBM34
Alfuzosin {u} (Compound) causes {v} (Side Effect) Coronary artery disease
Alfuzosin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nabilone
Alfuzosin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Morphine
Alfuzosin {u} may lead to a major life threatening interaction when taken with {v} Cobicistat
Alfuzosin (Compound) resembles Terazosin (Compound)
Alfuzosin (Compound) resembles Prazosin (Compound)
Alfuzosin (Compound) binds ADRA1A (Gene)
Alfuzosin (Compound) upregulates PAK1 (Gene)
Alfuzosin (Compound) downregulates RBM34 (Gene)
Alfuzosin (Compound) causes Coronary artery disease (Side Effect)
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Nabilone
Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Alfuzosin may lead to a major life threatening interaction when taken with Cobicistat